key: cord-0856801-kp9l624z authors: Živković, Sasha A.; Gruener, Gregory; Narayanaswami, Pushpa title: Doctor—Should I get the COVID‐19 vaccine? Infection and immunization in individuals with neuromuscular disorders date: 2021-01-27 journal: Muscle Nerve DOI: 10.1002/mus.27179 sha: c1c1e0964c4d956cc22b8d77efd631f10b1de342 doc_id: 856801 cord_uid: kp9l624z The clinical course of neuromuscular disorders (NMDs) can be affected by infections, both in immunocompetent individuals, and in those with reduced immunocompetence due to immunosuppressive/immunomodulating therapies. Infections and immunizations may also trigger NMDs. There is a potential for reduced efficacy of immunizations in patients with reduced immunocompetence. The recent vaccination program for coronavirus disease‐2019 (COVID‐19) raises several questions regarding the safety and efficacy of this vaccine in individuals with NMDs. In this Practice Topic article, we address the role of vaccine‐preventable infections in NMDs and the safety and efficacy of immunization in individuals with NMDs, with emphasis on vaccination against COVID‐19. Immunization against a disease may be achieved by natural infection or by vaccination against a specific agent or agents. The aim of vaccination is to generate an immune response against a particular antigen and protect susceptible populations from communicable diseases. This may be accomplished by the administration of a living modified agent ("live vaccine"; eg, yellow fever vaccine), a suspension of killed organisms (eg, pertussis vaccine), a protein expressed in a heterologous organism (eg, hepatitis B vaccine), or an inactivated toxin (eg, tetanus). 4 In this Practice Topic, we use the terms immunization and vaccination interchangeably to refer to immunity developed in response to vaccines. An increased risk mortality from influenza and increased rates of pneumococcal disease have been associated with NMDs. 5, 6 In a large population-based cohort study, MG was associated with a 39% increased risk of serious infections, mainly respiratory, compared with 19 .4% in the general population, over a mean follow-up period of 5.4 years (multivariate analysis with an adjusted hazard ratio, 1.39; 95% confidence interval [CI], 1.28-1.51). 7 Acute infections may, in turn, worsen respiratory function further, resulting in acute respiratory failure and the need for ventilatory assistance. Exacerbations of myasthenia gravis (MG) are commonly associated with infections. 8 In a recent study of 250 cases of myasthenic crisis requiring mechanical ventilation, the trigger for crisis was an infection in almost half of the patients. 9 In a retrospective cohort of patients under 21 years age and hospitalized with community-acquired influenza, concomitant NMDs were associated with higher risk of respiratory failure. 10 Infectious agents may directly cause NMDs (eg, cytomegalovirus [CMV] polyradiculopathy) or may trigger a postinfectious immune reaction (eg, acute inflammatory demyelinating polyneuropathy [AIDP] or Guillain-Barré syndrome [GBS] ). Acute anterior horn-cell involvement or poliomyelitis/acute flaccid paralysis is a feature of several viral infections, including poliovirus, 11 West Nile virus, 12 and enterovirus D68. 13 Human immunodeficiency virus (HIV) infection is associated with several types of NMDs, either directly or due to opportunistic infections. 14 Distal symmetrical, axonal, predominantly sensory polyneuropathy is the most common type of neuropathy in individuals with HIV. 15 Mononeuritis multiplex due to vasculitis is a rare complication of HIV infection. 16 A progressive polyradiculopathy due to opportunistic infection with CMV is well-known, but is also associated with lymphoma, tuberculosis, syphilis, and cryptococcus. 17 An amyotrophic lateral sclerosis (ALS)-like syndrome has been described with HIV infection. 18 HIV-associated polymyositis, nemaline myopathy, dermatomyositis, inclusion-body myositis, and necrotizing myopathy have been reported. 17 Reactivation of varicella zoster virus (VZV) causes herpes zoster or shingles, which is characterized by dermatomal vesicular eruption and pain affecting cranial or spinal nerves, and may be followed by postherpetic neuralgia. Reactivation of VZV infection is also associated with myelitis, cranial neuropathies, and rarely with segmental motor paresis resulting from VZV-related radiculopathies, plexopathies, or mononeuropathies. [19] [20] [21] Leprosy, caused by Mycobacterium leprae, is a common cause of neuropathy in developing countries. 22 Several bacteria, viruses, fungi, and parasites can cause infectious myositis. 23 Postinfectious de novo NMD is best exemplified by the association of AIDP/GBS with antecedent infections (Campylobacter jejuni, influenza, CMV, Epstein-Barr virus, Mycoplasma pneumoniae, Hemophilus influenzae, hepatitis E, Zika virus), where molecular mimicry is the proposed pathogenic mechanism. 24 One study showed that 18% of GBS patients during an influenza outbreak had serologic evidence of influenza. 25 There are recent reports of COVID-19-associated GBS (Section F). 26, 27 Infections can also trigger multisystemic and peripheral nerve vasculitides, including cryoglobulinemia (hepatitis C) and polyarteritis nodosa (hepatitis B [HBV]). 28, 29 Most of these infections are not vaccine-preventable except for influenza, H influenzae, and H zoster, and, most recently, COVID-19. IS/IM agents are commonly used in the treatment of autoimmune neuromuscular disorders, and vaccinations have a major role in reducing the morbidity associated with vaccine-preventable infections in this population. 30 There is a common perception that IS agents increase the risk of infections, both typical and atypical. A retrospective review of 631 patients with MG, chronic inflammatory demyelinating polyneuropathy (CIDP), and dermatomyositis who were on IS/IM agents revealed an infection rate of 19% in all three diseases, with pneumonia being the most frequent. There was a significant independent association between infections and the use of plasmapheresis, mycophenolate mofetil, and corticosteroids in multivariate analyses. Line infections due to plasmapheresis were not separately analyzed in that retrospective study. 31 Corticosteroids are associated with an increased risk of infections, including reactivation of latent tuberculosis. 32 B-cell-depleting therapies, such as rituximab, can reactivate HBV infections. The risk of reactivation is estimated at over 10% with rituximab or high-dose corticosteroid therapy (>20 mg/day prednisone for >14 consecutive days). 33 The risk of HBV reactivation with azathioprine, methotrexate, or low-dose corticosteroids (<10 mg/day prednisone) is estimated at less than 1%. 33 Reactivation of VZV infections has also been reported with the use of rituximab. 34 Progressive multifocal leukoencephalopathy (PML) due to reactivation 52, 53 At this time, the risk of GBS after influenza infection and the complications of influenza infection appear to outweigh the risk of influenza vaccine associated GBS. 50, 54 In CIDP, antecedent infections and vaccinations have been reported in 12% and 1.5%, respectively, within 6 weeks from onset. 55 Worsening of CIDP symptoms after tetanus vaccination has been reported in 8.7% of patients, but only 1 of 65 patients required treatment within 2 months from immunization. 56 There is no evidence of an association of idiopathic inflammatory myopathies and vaccinations, and the H1N1 vaccination appears to be safe and effective in patients with inflammatory myopathies. 57, 58 Overall, however, the risk of vaccination-triggered NMDs appears to be low, and should be evaluated in the context of the risk of NMDs being triggered or worsened by vaccine preventable infections. to the host-cell angiotensin-converting enzyme-2 receptor, mediating viral cell entry. It is targeted by host-neutralizing antibodies. 61 Envelope proteins form viroporins, small hydrophobic proteins necessary for viral assembly/release and mediate pathogenicity and cytotoxicity. 62 The membrane protein is the most abundant structural protein, providing a scaffold in assembly of the virus. 63 The nucleocapsid protein binds to viral RNA to form a ribonucleoprotein, which facilitates host-cell entry and interaction with cellular processes. 64 Recently, new variants of SARS-CoV-2 have been described in various parts of the world, including the UK, South Africa, and Nigeria. 65 The variant identified in the UK is referred to as SARS-CoV-2 VOC 202012/01 (the first variant of concern from December 2020). This variant appears to have increased transmissability. 66 The clinical picture of COVID-19 ranges from an asymptomatic illness to mildly symptomatic with respiratory or gastrointestinal symptoms, to a severe illness with coagulopathy and systemic multiorgan failure. 67 26, 67 The exact prevalence of COVID-19associated GBS remains uncertain because of potential ascertainment bias and selective reporting but appears to be low. 26, 27 It has been suggested that the spike protein of SARS-CoV-2 binds to sialic acid residues of gangliosides. This cross-reactivity to peripheral nerve gangliosides may trigger an immune reaction by molecular mimicry, resulting in GBS. 26 Society of America (IDSA) website provides updates on available studies. 84 The first vaccine to receive EUA by the FDA for individuals 16 Severe systemic effects were reported in more than 2% of participants. A median of at least 2 months of safety data was available for 37 706 participants, and the safety profile was reported as similar to that of other viral vaccines. Four related serious adverse events were reported: shoulder injury related to vaccine administration; right axillary lymphadenopathy; paroxysmal ventricular arrhythmia; and right leg paresthesia. 85 tracking programs such as V-safe by the CDC. 102 9. Based on current knowledge, it is believed that both COVID-19 mRNA vaccines in present use are unlikely to pose a risk to the pregnant person or fetus, but the potential risks are unknown. If pregnant women are a part of a group that is recommended to receive a COVID-19 vaccine, they should discuss the vaccination with their health-care team to help them make an informed decision. 103 EUA for first Covid19 vaccine US Food and Drug Administration. Moderna COVID-19 vaccine EUA letter of approval Respiratory implications of pediatric neuromuscular disease The evolution and genetics of innate immunity Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis Rates of pneumococcal disease in adults with chronic medical conditions Serious infections in patients with myasthenia gravis: population-based cohort study Myasthenia gravis and infectious disease Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection Neuromuscular manifestations of west nile virus infection Acute flaccid myelitis and enterovirus D68: lessons from the past and present Neuromuscular diseases associated with HIV-1 infection HIV neuropathy: insights in the pathology of HIV peripheral nerve disease Neuropathy in HIV infection Neuromuscular complications of HIV infection Retroviruses and amyotrophic lateral sclerosis Other neurological complications of herpes zoster and their management Clinical spectrum and prognosis of neurological complications of reactivated varicella-zoster infection: the role of immunosuppression Clinical, electrophysiologic, and imaging features of zoster-associated limb paresis Leprosy and the peripheral nervous system: basic and clinical aspects Bacterial, fungal, parasitic, and viral myositis Guillain-Barré syndrome Guillain-Barré syndrome and influenza virus infection COVID-19-associated Guillain-Barré syndrome: the early pandemic experience Incidence, clinical characteristics, risk factors and outcomes of Guillain-Barre syndrome in patients with Covid-19 Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy Polyarteritis nodosa neurologic manifestations Health maintenance for adults with neuromuscular diseases on immunosuppression Infections and the relationship to treatment in neuromuscular autoimmunity Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases Hepatitis B virus reactivation: risk factors and current management strategies Rituximab-related viral infections in lymphoma patients Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease International consensus guidance for management of myasthenia gravis: 2020 update Pneumocystis jirovecii pneumonia in the non-HIV-infected population Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults IDSA clinical practice guideline for vaccination of the immunocompromised host Altered immunocompetence. general best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP) Effect of methotrexate, antitumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis The effect of rituximab on vaccine responses in patients with immune thrombocytopenia Vaccination recommendations for patients with neuromuscular disease Vaccines and Guillain-Barré syndrome Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977 Guillain-Barré syndrome following influenza vaccination The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines Seasonal influenza vaccine and Guillain-Barré syndrome: a self-controlled case series study Guillain-Barré syndrome, influenza, and influenza vaccination: the epidemiologic evidence Guillain-Barré syndrome after exposure to influenza virus Recurrences, vaccinations and long-term symptoms in GBS and CIDP Recurrent Guillain-Barré syndrome following vaccination US Centers for Disease Control and Prevention. Guillain-Barré syndrome and vaccines 2020 Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP database Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation Pandemic unadjuvanted influenza a (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease A review on the association between inflammatory myopathies and vaccination World Health Organization. Weekly epidemiological update A new coronavirus associated with human respiratory disease in China Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses Role of the coronavirus E viroporin protein transmembrane domain in virus assembly Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy Structure of the N-terminal RNAbinding domain of the SARS CoV nucleocapsid protein World Health Organization US Centers for Disease Control and Prevention. SARS-CoV2 new variants The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. China Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic Guillain-Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection Critical illness myopathy after COVID-19 Nerve compression injuries after prolonged prone position ventilation in SARS-CoV-2 patient: a case series Upper trunk brachial plexopathy as a consequence of prone positioning due to SARS-CoV-2 acute respiratory distress syndrome Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-19 Muscle involvement in SARS-CoV-2 infection COVID-19-associated myositis may be dermatomyositis COVID-19-associated myositis with severe proximal and bulbar weakness COVID-19 and neuromuscular disorders Covid-19-associated myopathy caused by type I interferonopathy Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates Vaccine candidates with published results from Phase 1-3 clinical trials Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine COVID-19 vaccines and severe allergic reactions 2020 Efficacy and safety of the mRNA-1273 SARS co-V-2 vaccine The advisory committee on immunization practices' ethical principles for allocating initial supplies of COVID-19 vaccine-United States The advisory committee on immunization Practices' interim recommendation for allocating initial supplies of COVID-19 vaccine-United States US Centers for Disease Control and Prevention. High risk influenza populations 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis US Centers for Disease Control and Prevention. Latent tuberculosis infection. A guide for primary healthcare providers Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP) Pneumococcal vaccination: summary of who and when to vaccinate US Centers for Disease Control and Prevention. Frequently asked questions about Shingrix 2020 Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR. Recommendations and Reports Treatment and prevention of Pneumocystis pneumonia in HIV-uninfected patients pneumocystis-pneumonia-in-hiv-uninfected-patients?search= treatment-and-prevention-of-pneumocystis-pneumonia-in-non-hivinfected-patients%26x003F;source%26x003D Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States US Centers for Disease Control and Prevention. Covid vaccine safety Ensuring the safety of COVID-19 vaccines in the United States US Centers for Disease Control and Prevention. Live and inactivated vaccines Gleveckas-Martens DO How to cite this article: Živkovi c SA, Gruener G, Narayanaswami P, the AANEM Quality and Patient Safety Committee. Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders The authors thank Carrie Winter and Millie Suk (AANEM staff), Shirlyn Adkins JD (Executive Director of the AANEM), and the Board of Directors of the AANEM for their help and input. None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.